News
FENC
13.45
+0.90%
0.12
Fennec Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
Fennec Pharmaceuticals Price Target Raised to $17.00/Share From $16.00 by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $17
Benzinga · 1d ago
Fennec price target raised to $17 from $16 at H.C. Wainwright
TipRanks · 1d ago
H World Group Posts Upbeat Q3 Earnings, Joins CG Oncology, TELUS And Other Big Stocks Moving Higher On Monday
Benzinga · 3d ago
Fennec Pharmaceuticals Price Target Raised to $19.00/Share From $18.00 by B. Riley Securities
Dow Jones · 3d ago
B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $19
Benzinga · 3d ago
Fennec price target raised to $19 from $18 at B. Riley
TipRanks · 3d ago
Weekly Report: what happened at FENC last week (1109-1113)?
Weekly Report · 3d ago
What Makes Adherex Technologies (FENC) a New Strong Buy Stock
NASDAQ · 6d ago
We're Interested To See How Fennec Pharmaceuticals (NASDAQ:FENC) Uses Its Cash Hoard To Grow
Simply Wall St · 6d ago
Fennec Pharma (FENC) Q3 2026 Earnings Call Transcript
The Motley Fool · 11/12 16:31
Fennec Pharmaceuticals Q3 2026 Earnings Call Transcript
Benzinga · 11/12 14:30
Fennec Pharmaceuticals Swings To Profit In Q3 On Surging PEDMARK Sales; Stock Up
NASDAQ · 11/12 12:15
Adherex Technologies Inc. (FENC) Q3 Earnings and Revenues Beat Estimates
NASDAQ · 11/12 11:25
Fennec reports Q3 EPS 12c, consensus 11c
TipRanks · 11/12 11:20
Fennec Pharmaceuticals GAAP EPS of $0.12 beats by $0.02, revenue of $19.4M beats by $0.53M
Seeking Alpha · 11/12 11:16
Fennec Pharmaceuticals Q3 EPS $0.12 Beats $0.10 Estimate, Sales $19.608M Beat $18.401M Estimate
Benzinga · 11/12 11:14
*Fennec Pharmaceuticals 3Q EPS 12c >FRX.T
Dow Jones · 11/12 11:06
*Fennec Pharmaceuticals 3Q Adjusted EBITDA $5.8M >FRX.T
Dow Jones · 11/12 11:06
More
Webull provides a variety of real-time FENC stock news. You can receive the latest news about Fennec Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About FENC
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.